
-
Trump urges 60-day Gaza ceasefire deal ahead of Netanyahu visit
-
Partial verdict in Combs trial, jury will keep deliberating
-
Djokovic thanks 'miracle pills' after Wimbledon win
-
US college bans transgender athletes following swimming furor
-
Global stocks mixed as markets track US trade deal prospects
-
Djokovic up and running at Wimbledon in bid for Grand Slam history
-
Jury reaches partial verdict in Sean "Diddy" Combs trial
-
Giroud signs one-year deal with Ligue 1 club Lille
-
Gauff vows to make changes after shock Wimbledon exit
-
Gonzalo heads Real Madrid past Juventus and into Club World Cup quarters
-
Gauff crashes out of Wimbledon on day of shocks
-
Big automakers report US sales jump on pre-tariff consumer surge
-
'Alone' Zverev considers therapy after shock Wimbledon exit
-
Second seed Coco Gauff knocked out of Wimbledon
-
Switzerland comes to the aid of Red Cross museum
-
'That's life': No regrets for former champion Kvitova after Wimbledon farewell
-
AI videos push Combs trial misinformation, researchers say
-
UK govt guts key welfare reforms to win vote after internal rebellion
-
Polish supreme court ratifies nationalist's presidential vote win
-
Macron, Putin discuss Iran, Ukraine in first talks since 2022
-
French league launches own channel to broadcast Ligue 1
-
Man City left to reflect on Club World Cup exit as tournament opens up
-
Shock study: Mild electric stimulation boosts math ability
-
Europe swelters as surprise early summer heatwave spreads
-
Third seed Zverev stunned at Wimbledon
-
Israel expands Gaza campaign ahead of Netanyahu's US visit
-
Gaza mourns those killed in Israeli strike on seafront cafe
-
Rubio hails end of USAID as Bush, Obama deplore cost in lives
-
Berlusconi family sell Monza football club to US investment fund
-
UN aid meeting seeks end to Global South debt crisis
-
Trump ramps up Musk feud with deportation threat
-
French paparazzi boss handed 18-month suspended sentence for blackmail
-
Gilgeous-Alexander agrees record $285 mln extension: reports
-
Tearful former champion Kvitova loses on Wimbledon farewell
-
IMF urges Swiss to strengthen bank resilience
-
Sri Lanka eye top-three spot in ODI rankings
-
Trump hails new 'Alligator Alcatraz' migrant detention center
-
US Senate approves divisive Trump spending bill
-
Krejcikova toughs it out in Wimbledon opener, Sinner cruises
-
UK govt braces for crunch welfare reforms vote amid major rebellion
-
Shifting to Asia, Rubio meets Quad and talks minerals
-
Stocks diverge while tracking US trade deal prospects
-
Bruce Lee Club closes archive doors citing operating costs
-
Trump ramps up Musk feud with deportation, DOGE threats
-
BTS announces comeback for spring 2026
-
Beating England without Bumrah 'not impossible' for India captain Gill
-
Krejcikova battles back against rising star Eala to win Wimbledon opener
-
US Republicans close in on make-or-break Trump mega-bill vote
-
Arsenal sign goalkeeper Kepa from Chelsea
-
Olympic champion Zheng knocked out of Wimbledon

China approves first domestic mRNA vaccine for Covid-19
China has approved its first locally developed messenger RNA (mRNA) vaccine against Covid-19, its manufacturer said Wednesday, months after the relaxation of strict Covid-zero regulations sparked a surge in cases.
The vaccine, developed by CSPC Pharmaceutical Group Ltd, has been approved for "emergency use" by Beijing's health regulator, the company said in a statement.
It showed high efficacy in a trial in which it was used as a booster shot for people who have been given other types of vaccines, the company added, without offering further details.
mRNA vaccines are considered among the most effective in reducing severe infections and deaths.
While traditional vaccines use a weakened or inactivated germ to prepare the body for a future attack from the real virus, mRNA deploys snippets of genetic material that carry instructions showing the body's cells how to produce a protein -- in this case, the spike protein on the coronavirus that causes Covid.
The body's immune system then triggers antibodies to fight off that spike protein, making it ready for when the real coronavirus comes knocking.
Beijing has refused to greenlight mRNA-based vaccines from foreign firms Pfizer-BioNTech and Moderna for public use.
Its vaccination shortfall was widely believed to have led to more severe infections and deaths after lockdowns and mandatory quarantine rules were suddenly dropped in December.
Other Chinese drugmakers including CanSino have previously said they were developing mRNA-based shots to help the country bridge its immunisation gap.
M.A.Colin--AMWN